الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 93 |  |  |
| | | from | 93 | | |
Abstract
In this study, we investigated 46 cases for role of acute phase reactants predictors of clinical outcome of urinary bladder cancer. These cases 37 cases were metastatic cancer bladder & 9 cases were advanced cancer bladder. We correlated the expression of these markers in malignant bladder tumors with different clinical & his to pathological features that may affect the prognosis of these tumors no significant value. This study shows that there is no significant value for these tumor markers with age, gender or chief complaint of the patient.
Results of this study has shown that CRP good sensitive not specific , effect of treatment on level of CRP at different time measures in the whole group show significant value especially responding patients but no significant value in non-responding patients.
Also bladder cancer can raise ESR to high levels as was declared by the study result. High ESR has been found to correlate with overall poor prognosis after receiving treatment.
In patients with high sedimentation rate greater than 100 mm per hour usually indicates metastatic disease, but for most this relatively nonspecific finding and need more precise diagnostic tests.
Inflammatory biomarker show promising usefulness in the management of patients with cancer bladder, both for improved assessment of prognosis and to guide therapy. Serum CRP and ESR is the most promising inflammatory biomarker that predict outcome.
CRP and ESR as a role of representative cost- effective and noninvasive biomarker for systemic inflammatory response have a significant impact in predicting outcomes of urological cancer. This study suggests that elevated CRP and ESR are associated with poor prognosis in urological cancers which indicated that inflammation is involved in pathogenesis of cancer progression. These findings allow us to conclude that CRP and ESR might serve as a useful biomarker of disease outcome for urological cancers. Furthermore, the CRP and ESR kinetics of dynamic changes in CRP levels can be used to monitor the disease course, such as the effect of treatment intervention or further progression.